Vyome Holdings, Inc. HIND
1.57 USD 0.00 (-0.05%)
Nov 12, 2026, 10:10 AM EST
1.57 Day range 1.58
1.53 52-week range 5.88
- YTD
- -54.36%
- 1 year
- -70.49%
News
benzinga.com Vyome Holdings' ReShape Lifesciences Has Received A Notice Of Allowance For A U.S. Patent Titled "VAGUS NERVE NEUROMODULATION FOR THE TREATMENT OF THE HYPOGLYCEMIC STATE". https://patentcenter.uspto.gov/applications/18702356/ifw/docs
benzinga.com Vyome Holdings Appoints Jerry Leonard As CFO, Succeeding Robert Dickey IV, Who Served As Interim CFO Since August 2025 Finance executive with more than 25 years of experience brings extensive expertise in public company financial management, SEC reporting, financial operations, and governanceVyome Holdings, Inc.…
benzinga.com Chardan Capital Initiates Coverage On Vyome Holdings with Buy Rating, Announces Price Target of $3.5 Chardan Capital analyst Keay Nakae initiates coverage on Vyome Holdings (NASDAQ:HIND) with a Buy rating and announces Price Target of $3.5.
benzinga.com Vyome Appoints Jerry Leonard As CFO On August 27, 2026 On August 27, 2026, the board of directors (the "Board") of Vyome Holdings, Inc. (the "Company") appointed Jerry Leonard as the Company’s Chief Financial Officer. In connection with Mr. Leonard’s
benzinga.com 12 Health Care Stocks Moving In Friday's After-Market Session Gainers AbCellera Biologics (NASDAQ:ABCL) shares increased by 8.2% to $7.5 during Friday's after-market session. The company's market cap stands at $1.9 billion. As per the news, the Q2 earnings…- benzinga.com China National Intellectual Property Administration Grants Vyome Patent Chinese Patent No. ZL 2021 1 0758695.X Newly granted Chinese patent broadens Vyome's intellectual property estate with additional formulation and therapeutic use claims for besifloxacin gel in inflammatory acne, supporting future…
- benzinga.com Vyome Holdings Reports Data On Its Phase 2 Investigator Initiated Trial Results, Preclinical Data Of VT-1953 To Treat Symptoms Of Malignant Fungating Wounds At American Association For Cancer Research Annual Meeting Vyome Holdings, Inc. ("Vyome") (Nasdaq: HIND) presented its full Phase 2 investigator initiated study results and preclinical data supporting the efficacy and safety of VT-1953 as a potential…
benzinga.com Vyome Holdings To Present Full Phase 2 Investigator Initiated Study Results And Preclinical Data Supporting Efficacy And Safety Of VT-1953 As Potential Treatment For Malodor And Other Symptoms Of MFW At 2026 AACR Complete Phase 2 clinical data on the efficacy and safety of VT-1953 in MFW patients accepted for presentation at the annual meeting of the American Association for Cancer ResearchVyome Holdings,…- benzinga.com 12 Health Care Stocks Moving In Thursday's After-Market Session
benzinga.com Vyome Files For Orphan Drug Status For VT-1953, Its Lead Clinical Program Acceptance of Orphan Drug Status would confer certain anticipated US Market Exclusivity, R&D tax benefits, and PDUFA fee waiver of approximately $3MIndependent third-party assessment estimates a…- benzinga.com 12 Health Care Stocks Moving In Friday's Intraday Session
benzinga.com 12 Health Care Stocks Moving In Wednesday's Intraday Session 
benzinga.com 12 Health Care Stocks Moving In Monday's Pre-Market Session - benzinga.com 12 Health Care Stocks Moving In Wednesday's Intraday Session
- benzinga.com 12 Health Care Stocks Moving In Wednesday's Pre-Market Session
- benzinga.com Vyome Shares Move Higher; Co Highlights Independent Analyst Valuation Of Vyome Third-party analysis estimates the total addressable U.S. market to be approximately USD 2.2 billionModeled peak annual U.S. sales approaching USD 600 million for VT-1953Independent valuation…
benzinga.com 12 Health Care Stocks Moving In Thursday's After-Market Session - benzinga.com Vyome Holdings' Subsidiary LiveChain Enters Binding LOI To Acquire Humanyze Convertible Note In Equity Exchange with Remus Capital Entry into a Material Definitive Agreement Letter of Intent with LICH and Remus: On December 17, 2025, Vyome Holdings, Inc. (the "Company") entered into a binding letter of intent (the "LOI") among,…
- benzinga.com 12 Health Care Stocks Moving In Friday's Pre-Market Session
- benzinga.com 12 Health Care Stocks Moving In Tuesday's Pre-Market Session
benzinga.com Vyome's VT-1953 Announces Phase 2 Efficacy In Malignant Fungating Wounds, Paving Path To Pivotal Trial VT-1953 treatment over 14 days resulted in highly statistically significant improvements in bad smell or malodor associated with malignant fungating wound (primary endpoint) (P =…- benzinga.com 12 Health Care Stocks Moving In Friday's After-Market Session
- benzinga.com Vyome Acquires Oculo, An AI Startup Launched At The Massachusetts Institute Of Technology And Launched A New Business Unit Focused On Using AI To Tackle Inflammation; Deal Terms Were Undisclosed This new business unit will leverage Oculo's assets to develop an AI psychiatrist trained on data from both the US and India, and will be overseen by a newly-formed Vyome Board of Directors AI…
- benzinga.com 12 Health Care Stocks Moving In Wednesday's Pre-Market Session
- benzinga.com Market-Moving News for September 17th SPRC: 268% | SciSparc shares are trading higher after Automax Motors filed a motion to Jerusalem District Court in connection with its merger with the company. HIND: 199% | Vyome Unveils Preclinical…
- benzinga.com Vyome Unveils Preclinical Data For VT-1908 Eye Drops To Treat Uveitis, A Leading Cause Of Blindness Vyome Holdings, Inc. (NASDAQ:HIND), a clinical-stage healthcare holding company, presented results from its preclinical studies investigating VT-1908 (the first topical formulation of mycophenolate)…
benzinga.com Deal Dispatch: Musk-Altman Drama, Ashton Kutcher SoHo House Play And We Pose Questions To Private Equity Pros Elon's OpenAI bid flops, Vyome reviews Livechain, Peraso courts acquirers, GTCR faces antitrust and pizza chains go bankrupt.- benzinga.com 12 Health Care Stocks Moving In Monday's Intraday Session
benzinga.com Empery Digital, Riskified And Other Big Stocks Moving Lower In Monday's Pre-Market Session - benzinga.com 12 Health Care Stocks Moving In Monday's Pre-Market Session
- benzinga.com 12 Health Care Stocks Moving In Friday's After-Market Session